Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOVO-112
- Development stage
- Preclinical
- Lead developer
- InnovoTEX
- Modality
- Small Molecules
01
Overview
NOVO-112 is a preclinical-stage macrocycle drug conjugate (MDC) being developed by InnovoTEX for the treatment of breast cancer and melanoma. It utilizes a phototherapy/photothermal mechanism to thermally heat tumors using ultrasound, inducing hyperthermia to destroy cancer cells. Unlike traditional photodynamic therapies, NOVO-112's mechanism is non-reactive-oxygen-species (ROS) generating, which helps minimize off-target oxidative damage. The candidate is currently in the proof-of-concept (POC) and discovery stage of development.
Beyond the preview
Go deeper on NOVO-112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOVO-112.